Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Equities research analysts at Zacks Research decreased their Q1 2026 EPS estimates for shares of Dr. Reddy's Laboratories in a research note issued on Thursday, February 6th. Zacks Research analyst R. Department now anticipates that the company will earn $0.19 per share for the quarter, down from their previous forecast of $0.20. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' Q1 2027 earnings at $0.17 EPS and FY2027 earnings at $0.60 EPS.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%.
Other research analysts also recently issued research reports about the stock. Nomura downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. Barclays decreased their price objective on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Finally, StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.
View Our Latest Stock Report on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Stock Up 1.6 %
Shares of RDY traded up $0.22 during midday trading on Monday, hitting $14.02. The company had a trading volume of 2,497,317 shares, compared to its average volume of 2,006,514. The company's 50-day simple moving average is $14.75 and its 200-day simple moving average is $15.32. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories has a 1 year low of $13.36 and a 1 year high of $16.89. The firm has a market capitalization of $11.70 billion, a P/E ratio of 22.32 and a beta of 0.50.
Institutional Investors Weigh In On Dr. Reddy's Laboratories
A number of institutional investors and hedge funds have recently bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its stake in Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Dr. Reddy's Laboratories by 382.9% in the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after buying an additional 7,467,979 shares during the last quarter. Aikya Investment Management Ltd raised its stake in Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after acquiring an additional 4,523,303 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after purchasing an additional 3,911,404 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Dr. Reddy's Laboratories by 462.1% in the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after acquiring an additional 2,313,987 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.
Dr. Reddy's Laboratories Company Profile
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Articles
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
